Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
- Conditions
- Age Related Macular Degeneration
- Interventions
- Registration Number
- NCT00593450
- Lead Sponsor
- University of Pennsylvania
- Brief Summary
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.
A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.
- Detailed Description
Age related macular degeneration (AMD) is the leading cause of severe vision loss in people over the age of 65 in the United States and other Western countries. More than 1.6 million people in the US currently have one or both eyes affected by the advanced stage of AMD.
Lucentis® is the most effective treatment for neovascular AMD studied to date. Bevacizumab (Avastin®) and Lucentis® are derived from the same monoclonal antibody. Following the encouraging clinical trial results with Lucentis®, several investigators began evaluating intravitreal Avastin® for the treatment of CNV. Given its molecular similarity to Lucentis, its low cost, and its availability, the interest in Avastin® has been considerable. Avastin® has not been evaluated relative to Lucentis®.
In addition, previous studies do not answer the question of whether a reduced dosing schedule is as effective as a fixed schedule of monthly injections. Treatment dependent on clinical response has the potential to reduce the treatment burden to patients as well as to reduce the overall cost of therapy.
Only a single eye in each patient was analyzed.
At the five year follow-up visit, the subjects will undergo the same examinations and procedures as in the original study; however, the five year follow-up visit deos not involve any study treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1208
- Active, subfoveal choroidal neovascularization (CNV)
- Fibrosis < 50% of total lesion area
- Visual acuity (VA) 20/25-20/320
- Age ≥ 50 yrs
- At least 1 drusen (>63μ) in either eye or late AMD in fellow eye
- Previous treatment for CNV in study eye
- Other progressive retinal disease likely to compromise VA
- Contraindications to injections with Lucentis or Avastin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 3 ranibizumab Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity. 1 ranibizumab Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing. 2 bevacizumab Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing. 4 bevacizumab Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
- Primary Outcome Measures
Name Time Method Change From Baseline in Visual-acuity Score (Continuous) Baseline and 1 Year Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.
In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement.
- Secondary Outcome Measures
Name Time Method Number of Treatments 1 Year Cumulative over the 1 year of trial
Visual-acuity Score and Snellen Equivalent (Frequency) at 1 Year Visual-acuity Score and Snellen Equivalent (Continuous) at 1 Year Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.
In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity.Change in Diastolic Blood Pressure From Baseline Baseline and 1 Year Change From Baseline Visual-acuity Score (Frequency) Baseline and 1 Year Total Thickness Change From Baseline at Fovea Baseline and 1 Year Retinal Thickness Plus Subfoveal-fluid Thickness Change From Baseline at Fovea Baseline and 1 Year Fluid on Optical Coherence Tomography at 1 Year Average Cost of Drug/Patient at 1 Year Total Thickness at Fovea at 1 Year Area of Lesion at 1 Year Retinal Thickness Plus Subfoveal-fluid Thickness at Fovea at 1 Year Change in Systolic Blood Pressure From Baseline Baseline and 1 Year Dye Leakage on Angiogram at 1 Year Area of Lesion Change From Baseline Baseline and 1 Year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (51)
Retina Consultants of Arizona
🇺🇸Mesa, Arizona, United States
Retinal Consultants of Arizona
🇺🇸Phoenix, Arizona, United States
Retina Associates Southwest, P.C.
🇺🇸Tucson, Arizona, United States
California Retina Consultants
🇺🇸Bakersfield, California, United States
Retina-Vitreous Associates Medical Group
🇺🇸Beverly Hills, California, United States
University of California-Davis Medical Center
🇺🇸Sacramento, California, United States
Retinal Consultants Medical Group, Inc.
🇺🇸Sacramento, California, United States
West Coast Retina Medical Group, Inc.
🇺🇸Walnut Creek, California, United States
California Retinal Consultants
🇺🇸Santa Barbara, California, United States
Colorado Retina Associates
🇺🇸Denver, Colorado, United States
Scroll for more (41 remaining)Retina Consultants of Arizona🇺🇸Mesa, Arizona, United States